Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Bolt Biotherapeutics (BOLT) Income towards Parent Company (2020 - 2025)

Bolt Biotherapeutics (BOLT) has disclosed Income towards Parent Company for 6 consecutive years, with -$6.7 million as the latest value for Q4 2025.

  • Quarterly Income towards Parent Company rose 57.84% to -$6.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$33.6 million through Dec 2025, up 50.41% year-over-year, with the annual reading at -$33.6 million for FY2025, 50.41% up from the prior year.
  • Income towards Parent Company hit -$6.7 million in Q4 2025 for Bolt Biotherapeutics, up from -$7.2 million in the prior quarter.
  • In the past five years, Income towards Parent Company ranged from a high of -$6.7 million in Q4 2025 to a low of -$27.2 million in Q4 2021.
  • Historically, Income towards Parent Company has averaged -$17.6 million across 5 years, with a median of -$18.0 million in 2023.
  • Biggest five-year swings in Income towards Parent Company: tumbled 113.27% in 2021 and later soared 59.37% in 2025.
  • Year by year, Income towards Parent Company stood at -$27.2 million in 2021, then increased by 26.37% to -$20.0 million in 2022, then grew by 10.47% to -$17.9 million in 2023, then grew by 10.99% to -$15.9 million in 2024, then surged by 57.84% to -$6.7 million in 2025.
  • Business Quant data shows Income towards Parent Company for BOLT at -$6.7 million in Q4 2025, -$7.2 million in Q3 2025, and -$8.6 million in Q2 2025.